Iressa Expanded Access Program (EAP)

Phase 3

Completed

• Conditions: Carcinoma; Non-small-cell Lung; Metastases; Neoplasm

• Registration Number: NCT00034879
• Lead Sponsor: AstraZeneca

Brief Summary

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-08
• Study First Submitted: 2002-05-02
• Study First Submitted QC: 2002-05-02
• Study First Posted: 2002-05-03
• Primary Completion: 2003-10
• Study Completion: 2003-10
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-03
• Last Update Posted: 2013-01-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Research Site; 🇺🇸 Cheyenne, Wyoming, United States